Theophylline bioequivalence

Abstract. A three-way crossover study in 18 healthy male volunteers was conducted to evaluate the bioequivalence of three different 200 mg anhydrous. Objective: To determine whether a generic slow-release theophylline tablet (manufactured by Sidmak Laboratories, Inc.) is therapeutically equivalent to a. On Jun 1, 1992 M Mazzei (and others) published: HPLC analysis of theophylline: bioequivalence study of two sustained-release formulations at steady state. Objective: To determine whether a generic slow-release theophylline tablet (manufactured by Sidmak Laboratories, Inc.) is therapeutically equivalent to a propri.

Vidyodaya (.) Golden Jubilee Issue pp 185 - 194. Formulation of Extended Release Theophylline Tablets. Experimental, Modelling and Bioequivalence Studies. J Pediatr. 1994 Dec;125(6 Pt 1):987-91. Bioequivalence of a generic slow-release theophylline tablet in children. Kanthawatana S(1), Ahrens RC, McCubbin M. Active ingredient: Theophylline. Form/Route: Tablet, Extended Release/ Oral. Recommended studies: 2 studies. 1.

Type of study: Fasting Bioequivalence study. The objective of this study was to determine the bioequivalence of two theophylline (CAS 58-55-9) sustained release formulations containing 400 mg. Bioequivalence of a generic slow-release theophylline tablet in children Kanthawatana S, Ahrens RC, McCubbin M, Bronsky E, Blake K, Hendeles L.J Pediatr. Bioequivalence (95-105%), while for product B the T/R ratio was not satisfactory. Conclusions: None of the test products of theophylline were.

Arzneimittelforschung. 1998 Mar;48(3):259-62. Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J(1). RESULTS. The 90% confidence interval of Cmax, t1/2 and CL/F of theophylline with The bioequivalence of theophylline in the absence and. Farmaco. 1992 May;47(5 Suppl):769-77. HPLC analysis of theophylline: bioequivalence study of two sustained-release formulations at steady state.

Mazzei.

© 2017 iqbazar.ru